Related references
Note: Only part of the references are listed.Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X. Zhu et al.
BRITISH JOURNAL OF CANCER (2021)
Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
Xuqi Sun et al.
BMC CANCER (2021)
Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
Issei Saeki et al.
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Robin Kate Kelley et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2019)
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Peter R. Galle et al.
LIVER INTERNATIONAL (2019)
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
Yu-Yun Shao et al.
LIVER INTERNATIONAL (2019)
Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma A meta-analysis
Chao He et al.
MEDICINE (2019)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review
Wen-Chi Chou et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2018)
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
PLOS ONE (2015)
Early alpha-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
Sangheun Lee et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2015)
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
Takahide Nakazawa et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2013)
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
Nicola Personeni et al.
JOURNAL OF HEPATOLOGY (2012)
Evaluation of the mRECIST and alpha-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
Tomokazu Kawaoka et al.
ONCOLOGY (2012)
Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma
Xin-Sen Xu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
Thomas Yau et al.
ONCOLOGIST (2011)
Early Decrease in alpha-Fetoprotein, but Not Des-gamma-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma
Teiji Kuzuya et al.
ONCOLOGY (2011)
Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients With Advanced Hepatocellular Carcinoma
Yu-Yun Shao et al.
CANCER (2010)
New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
Stephen L. Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Serum alpha-Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma
Sadhna R. Vora et al.
ONCOLOGIST (2009)
α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma
LT Chen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Statistics review 13: Receiver operating characteristic curves
V Bewick et al.
CRITICAL CARE (2004)
Share Paper
